System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 39513004 DOI: 10.1007/s12195-024-00817-y

Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian Cancer.

Cell Mol Bioeng 17(5):345-367

Authors: Simona Plesselova, Kristin Calar, Hailey Axemaker, Emma Sahly, Amrita Bhagia, Jessica L Faragher, Darci M Fink, Pilar de la Puente

Affiliations

  • Present Address: Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD USA.
  • Present Address: Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD USA. St. Olaf College, Northfield, MN USA.
  • MD PhD Program, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD USA.
  • Present Address: Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD USA. MD PhD Program, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD USA.
  • Department of Chemistry, Biochemistry & Physics, South Dakota State University, Brookings, SD USA.
  • Department of Obstetrics and Gynecology, University of South Dakota Sanford School of Medicine, Sioux Falls, SD USA.
  • Department of Surgery, University of South Dakota Sanford School of Medicine, Sioux Falls, SD USA.
  • Flow Cytometry Core, Sanford Research, Sioux Falls, SD USA.

Abstract

Introduction

The majority of ovarian cancer (OC) patients receiving standard of care chemotherapy develop chemoresistance within 5 years. The tumor microenvironment (TME) is a dynamic and influential player in disease progression and therapeutic response. However, there is a lack of models that allow us to elucidate the compartmentalized nature of TME in a controllable, yet physiologically relevant manner and its critical role in modulating drug resistance.

Methods

We developed a 3D microvascularized multiniche tumor-on-a-chip formed by five chambers (central cancer chamber, flanked by two lateral stromal chambers and two external circulation chambers) to recapitulate OC-TME compartmentalization and study its influence on drug resistance. Stromal chambers included endothelial cells alone or cocultured with normal fibroblasts or cancer-associated fibroblasts (CAF).

Results

The tumor-on-a-chip recapitulated spatial TME compartmentalization including vessel-like structure, stromal-mediated extracellular matrix (ECM) remodeling, generation of oxygen gradients, and delayed drug diffusion/penetration from the circulation chamber towards the cancer chamber. The cancer chamber mimicked metastasis-like migration and increased drug resistance to carboplatin/paclitaxel treatment in the presence of CAF when compared to normal fibroblasts. CAF-mediated drug resistance was rescued by ECM targeted therapy. Critically, these results demonstrate that cellular crosstalk recreation and spatial organization through compartmentalization are essential to determining the effect of the compartmentalized OC-TME on drug resistance.

Conclusions

Our results present a functionally characterized microvascularized multiniche tumor-on-a-chip able to recapitulate TME compartmentalization influencing drug resistance. This technology holds the potential to guide the design of more effective and targeted therapeutic strategies to overcome chemoresistance in OC.

Supplementary Information

The online version contains supplementary material available at 10.1007/s12195-024-00817-y.

MeSH

Pharmaceutical Preparations, Neoplasms, Ovarian Neoplasms, Fibroblasts, Therapeutics, Drug Resistance

Cited by